Head-to-head comparison of 11C-PiB and 18F-FC119S for Aβ imaging in healthy subjects, mild cognitive impairment patients, and Alzheimer's disease patients

被引:23
作者
Byun, Byung Hyun [1 ]
Kim, Byung Il [1 ]
Park, Su Yeon [2 ]
Ko, In Ok [3 ]
Lee, Kyo Chul [3 ]
Kim, Kyeong Min [3 ]
Kim, Yu Kyeong [4 ]
Lee, Jun-Young [5 ]
Bu, Seon Hee [6 ]
Kim, Jung Hwa [6 ]
Chi, Dae Yoon [7 ,8 ]
Ha, Jeong Ho [2 ]
Lim, Sang Moo [1 ]
机构
[1] Seoul Natl Univ, Dept Nucl Med, Seoul, South Korea
[2] Seoul Natl Univ, Korea Canc Ctr Hosp, Dept Neurol, Seoul, South Korea
[3] Seoul Natl Univ, Mol Imaging Res Ctr, Korea Inst Radiol & Med Sci, Seoul, South Korea
[4] Seoul Natl Univ, Dept Nucl Med, Seoul, South Korea
[5] Seoul Natl Univ, Boramae Hosp, Coll Med, Dept Psychiat & Behav Sci, Seoul, South Korea
[6] Seoul Bukbu Hosp, Dept Neurol, Seoul, South Korea
[7] FutureChem Co Ltd, Res Inst Labeling, Seoul, South Korea
[8] Sogang Univ, Dept Chem, Seoul, South Korea
关键词
Alzheimer's disease; beta amyloid (A beta); PET; PITTSBURGH COMPOUND-B; AMYLOID DEPOSITION; PET; FLORBETAPIR; F-18-FLORBETABEN; QUANTIFICATION;
D O I
10.1097/MD.0000000000006441
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
As a new beta amyloid (Ab) positron emission tomography (PET) tracer, F-18-FC119S has shown higher cortical uptake in patients with Alzheimer's disease (AD) than that in healthy control subjects without adverse effects in a previous preliminary study. The aim of this study was to compare F-18-FC119S PET and C-11-PiB PET in healthy control (HC) subjects, mild cognitive impairment (MCI) patients, and AD patients. A total of 48 subjects, including 28 HC subjects, 10 MCI patients, and 10 AD patients, underwent static F-18-FC119S PET (30 minutes after intravenous [i.v.] injection) and C-11-PiB PET (40 minutes after i. v. injection) on the same day. Both PET images were visually and quantitatively assessed. Standardized uptake value ratios (SUVRs) were calculated for each brain region using the cerebellar cortex as a reference region. None (0%) of the 28 HC subjects and 4 (40%) of 10 MCI patients had positive scans on both PET images. Of the 10 AD patients, 7 (70%) had positive scans on 11C-PiB PET while 6 (60%) had positive scans on F-18-FC119S PET. Overall, 47 (98%) of 48 participants showed identical results based on visual analysis. Cortical SUVR of F-18-FC119S was higher in AD patients (1.38 +/- 0.16), followed by that in MCI patients (1.24 +/- 0.10) and in HC subjects (1.14 +/- 0.05). Compared with C-11-PiB PET, F-18-FC119S PET yielded a higher effect size (d= 2.02 vs. 1.67) in AD patients and a slightly lower effect size (d= 1.26 vs. 1.38) in MCI patients. In HC subjects, the nonspecific binding of F-18-FC119S to white matter (with the frontal cortex-to-white matter SUV ratio of 0.76) was slightly lower than that of C-11-PiB ( ratio of 0.73). There was a significant linear correlation (slope= 0.41, r= 0.78, P< 0.001) between C-11-PiB and (18)FFC119S cortical SUVR. We could safely obtain images similar to C-11-PiB PET imaging Ab in the brain using F-18-FC119S PET. Therefore, F-18-FC119S might be suitable for imaging Ab deposition.
引用
收藏
页数:7
相关论文
共 31 条
  • [21] [11C]PIB-amyloid binding and levels of Aβ40 and Aβ42 in postmortem brain tissue from Alzheimer patients
    Svedberg, Marie M.
    Hall, Hakan
    Hellstrom-Lindahl, Ewa
    Estrada, Sergio
    Guan, ZhiZhong
    Nordberg, Agneta
    Langstrom, Bengt
    [J]. NEUROCHEMISTRY INTERNATIONAL, 2009, 54 (5-6) : 347 - 357
  • [22] Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain
    Tzourio-Mazoyer, N
    Landeau, B
    Papathanassiou, D
    Crivello, F
    Etard, O
    Delcroix, N
    Mazoyer, B
    Joliot, M
    [J]. NEUROIMAGE, 2002, 15 (01) : 273 - 289
  • [23] 18F-Flutemetamol Amyloid Imaging in Alzheimer Disease and Mild Cognitive Impairment A Phase 2 Trial
    Vandenberghe, Rik
    Van Laere, Koen
    Ivanoiu, Adrian
    Salmon, Eric
    Bastin, Christine
    Triau, Eric
    Hasselbalch, Steen
    Law, Ian
    Andersen, Allan
    Korner, Alex
    Minthon, Lennart
    Garraux, Gaetan
    Nelissen, Natalie
    Bormans, Guy
    Buckley, Chris
    Owenius, Rikard
    Thurfjell, Lennart
    Farrar, Gill
    Brooks, David J.
    [J]. ANNALS OF NEUROLOGY, 2010, 68 (03) : 319 - 329
  • [24] Aβ Imaging: feasible, pertinent, and vital to progress in Alzheimer's disease
    Villemagne, Victor L.
    Klunk, William E.
    Mathis, Chester A.
    Rowe, Christopher C.
    Brooks, David J.
    Hyman, Bradley T.
    Ikonomovic, Milos D.
    Ishii, Kenji
    Jack, Clifford R.
    Jagust, William J.
    Johnson, Keith A.
    Koeppe, Robert A.
    Lowe, Val J.
    Masters, Colin L.
    Montine, Thomas J.
    Morris, John C.
    Nordberg, Agneta
    Petersen, Ronald C.
    Reiman, Eric M.
    Selkoe, Dennis J.
    Sperling, Reisa A.
    Van Laere, Koen
    Weiner, Michael W.
    Drzezga, Alexander
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 (02) : 209 - 219
  • [25] Amyloid PET Ligands for Dementia
    Villemagne, Victor L.
    Rowe, Christopher C.
    [J]. PET CLINICS, 2010, 5 (01) : 33 - 53
  • [26] Amyloid Imaging with 18F-Florbetaben in Alzheimer Disease and Other Dementias
    Villemagne, Victor L.
    Ong, Kevin
    Mulligan, Rachel S.
    Holl, Gerhard
    Pejoska, Svetlana
    Jones, Gareth
    O'Keefe, Graeme
    Ackerman, Uwe
    Tochon-Danguy, Henri
    Chan, J. Gordon
    Reininger, Cornelia B.
    Fels, Lueder
    Putz, Barbara
    Rohde, Beate
    Masters, Colin L.
    Rowe, Christopher C.
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2011, 52 (08) : 1210 - 1217
  • [27] The magnitude of dementia occurrence in the world
    Wimo, A
    Winblad, B
    Aguero-Torres, H
    von Strauss, E
    [J]. ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 2003, 17 (02) : 63 - 67
  • [28] Mild cognitive impairment -: beyond controversies, towards a consensus:: report of the International Working Group on Mild Cognitive Impairment
    Winblad, B
    Palmer, K
    Kivipelto, M
    Jelic, V
    Fratiglioni, L
    Wahlund, LO
    Nordberg, A
    Bäckman, L
    Albert, M
    Almkvist, O
    Arai, H
    Basun, H
    Blennow, K
    de Leon, M
    DeCarli, C
    Erkinjuntti, T
    Giacobini, E
    Graff, C
    Hardy, J
    Jack, C
    Jorm, A
    Ritchie, K
    van Duijn, C
    Visser, P
    Petersen, RC
    [J]. JOURNAL OF INTERNAL MEDICINE, 2004, 256 (03) : 240 - 246
  • [29] Amyloid imaging in Alzheimer's disease: comparison of florbetapir and Pittsburgh compound-B positron emission tomography
    Wolk, David A.
    Zhang, Zheng
    Boudhar, Sanaa
    Clark, Christopher M.
    Pontecorvo, Michael J.
    Arnold, Steven E.
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2012, 83 (09) : 923 - 926
  • [30] In Vivo Imaging of Amyloid Deposition in Alzheimer Disease Using the Radioligand 18F-AV-45 (Flobetapir F 18)
    Wong, Dean F.
    Rosenberg, Paul B.
    Zhou, Yun
    Kumar, Anil
    Raymont, Vanessa
    Ravert, Hayden T.
    Dannals, Robert F.
    Nandi, Ayon
    Brasic, James R.
    Ye, Weiguo
    Hilton, John
    Lyketsos, Constantine
    Kung, Hank F.
    Joshi, Abhinay D.
    Skovronsky, Daniel M.
    Pontecorvo, Michael J.
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2010, 51 (06) : 913 - 920